Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Endocrinology
Can a patient with a PMHx of pancreatic injury or disease (i.e. blunt trauma, recurrent pancreatitis) take a GLP-1 agonist safely in the setting of morbid obesity and type 2 diabetes?
Related Questions
Is there a role for using continuous glucose monitors for perioperative glucose monitoring in patients with diabetes?
When do you recommend screening patients with T2DM for heart failure?
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
How do you interpret the presence of GAD antibody in a middle-aged patient with diabetes when all other type 1 diabetes antibodies are absent?
Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?
Should GLP1 R agonists be used as first line glucose lowering agents in patients with ESKD and DM2?
Do you prioritize dietary modifications and exercise over early pharmacologic interventions, such as metformin or insulin, for women diagnosed with gestational diabetes?
Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?
Do you regularly counsel younger women of childbearing age about the impact of Tirzepatide on oral hormonal contraception?
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
